Extrapyramidal side-effects of antipsychotics in a randomised trial

British Journal of Psychiatry

Volumn 193, Issue 4, 2008, Pages 279-288

  Miller, Del D ^a,b   Caroff, Stanley N ^a,c   Davis, Sonia M ^a,d   Rosenheck, Robert A ^a,e   McEvoy, Joseph P ^a,f   Saltz, Bruce L ^a,g   Riggio, Silvana ^a,h   Chakos, Miranda H ^a,i   Swartz, Marvin S ^a,f   Keefe, Richard S E ^a,f   Stroup, T Scott ^a,j   Lieberman, Jeffrey A ^a,k  

^a Clinical Antipsychotic Trials of Intervention Effectiveness ^*

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d IQVIA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY   (United States)

^g Mental Health Advocates Inc   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k College of Physicians and Surgeons ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AKATHISIA; ARTICLE; BARNES AKATHISIA RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARKINSONISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIMPSON ANGUS RATING SCALE; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 53949112680     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.050088     Document Type: Article

References (51)

1. Arvanitis la, Miller BG. Multiple fixed closes of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-46.
2. Daniel DG, Zimbroff dl, Potkin SG, Reeves kr, Harrigan EP, lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial, ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505.
3. Kane JM, Woerner M, Lieberman J. Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 (suppl): 52-6.
4. Marder SR, Meibach rc. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
5. Potkin SG, Sana AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90.
6. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-74.
7. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-6.
8. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
9. Jones pb, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
10. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren s, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693-702.
11. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
12. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006; 67: 897-903.
13. Rosenheck R, Stroup S, Keefe RSE, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. Measuring outcome priorities and preferences in people with schizophrenia. Br J Psychiatry 2005; 187: 529-36.
14. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25.
15. Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 259-63.
16. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 (suppl 4): 15-20.
17. Glazer WM, Morgenstem H, Doucette jt. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-9.
18. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984; 20: 387-9.
19. Miller dd, McEvoy jp, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 33-43.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
21. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11-9.
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
23. Guy W. Abnormal involuntary movement scale (AIMS). In ECDEU Assessment Manual for Psychopharmacology Revised: 534-7. Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, 1976.
24. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415-27.
25. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31.
26. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-7.
27. Hochberg Y. A shaper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-3.
28. Stokes me, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. SAS Institute Inc, 2000.
29. Chakos MH, Alvir JM, woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53: 313-9.
30. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61 (suppl 4): 10-4.
31. Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006; 21: 35-42.
32. Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006; 163: 938-9.
33. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150-5.
34. Lee C, Wu KH, Habil H, Dyachkova Y, Lee P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust N Z J Psychiatry 2006; 40: 437-45.
35. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142-5.
36. Gourzis P, Polychronopoulos P, Papapetropoulos S, Assimakopoulos K, Argyriou AA, Beratis S. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clin Neuropharmacol 2005; 28: 195-6.
37. Grant MJ, Baldessarini RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005; 39: 1953.
38. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293-301.
39. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 985-96.
40. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318-22.
41. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-98.
42. Kane JM, Leucht S, Carpenter D, Docherty JP; for the Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 (suppl 12): 5-19.
43. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Costeffectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080-9.
44. swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428-36.
45. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer hy. Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATlE Trial. Arch Gen Psychiatry 2007; 64: 633-47.
46. Kelsey jl, Whittemore AS, Evans AS, Thompson DS. Methods in Observational Epidemiology (2nd edn): 88-9. oxford University Press, 1996.
47. Crane GE. Prevention and management of tardive dyskinesia. Am J psychiatry 1972; 129: 466-7.
48. Kane JM, Woerner M, Borenstein M, wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254-8.
49. Saltz BL, woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-6.
50. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22: 475-83.
51. Rosenheck R, Stroup T, swartz M, Mcevoy J, Davis S, Keefe R, Hsiao J, Lieberman J. Dr. Rosenheck and Colleagues Reply. Am J Psychiatry 2007; 164: 678-80.